Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer

Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer

Patients with triple-negative breast cancer (TNBC) suffer an unfavorable prognosis. Carboplatin (CBDCA) as a cytotoxic reagent has been widely administered to patients with cancer including TNBC. Programmed cell death protein 1 (PD-1) is an immune checkpoint, blockade of which unleashes T cell funct...

Full description

Bibliographic Details
Main Authors: Meizhuo Gao, Tie Wang, Litong Ji, Shuping Bai, Lining Tian, Hongjiang Song
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-03-01
Series:Frontiers in Immunology
Subjects:
triple-negative breast cancer
carboplatin
immune checkpoint inhibitor
surgery
tumor microenvironment
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.00366/full

Similar Items

Similar Items